Catalyst
Slingshot members are tracking this event:
Merck’s KEYTRUDA (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MRK |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 02, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Keytruda, Pembrolizumab, European Commission, Advanced Non-small Cell Lung Cancer, Nsclc, Tumor, Pd-l1, Keynote-010, Chemotherapy
